A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 147,400 shares of SLS stock, worth $184,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares
147,400
Previous 266,000 44.59%
Holding current value
$184,250
Previous $281,000 47.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.51 - $1.55 $10,056 - $30,562
19,718 New
19,718 $19,000
Q2 2023

Aug 14, 2023

BUY
$1.35 - $1.8 $4,268 - $5,691
3,162 New
3,162 $4,000
Q4 2022

Feb 14, 2023

SELL
$2.02 - $5.41 $210,453 - $563,640
-104,185 Reduced 96.86%
3,375 $7,000
Q3 2022

Nov 14, 2022

BUY
$2.1 - $3.38 $146,834 - $236,332
69,921 Added 185.77%
107,560 $217,000
Q2 2022

Aug 15, 2022

BUY
$2.14 - $4.15 $51,935 - $100,716
24,269 Added 181.52%
37,639 $84,000
Q1 2022

May 16, 2022

SELL
$4.73 - $7.18 $129,947 - $197,256
-27,473 Reduced 67.26%
13,370 $89,000
Q4 2021

Feb 14, 2022

SELL
$5.36 - $9.53 $8,822 - $15,686
-1,646 Reduced 3.87%
40,843 $225,000
Q3 2021

Nov 15, 2021

BUY
$8.21 - $10.53 $227,072 - $291,238
27,658 Added 186.49%
42,489 $389,000
Q2 2021

Aug 16, 2021

SELL
$7.19 - $13.71 $68,793 - $131,177
-9,568 Reduced 39.21%
14,831 $164,000
Q1 2021

May 17, 2021

BUY
$5.5 - $11.71 $134,194 - $285,712
24,399 New
24,399 $208,000
Q2 2020

Aug 14, 2020

SELL
$1.53 - $3.93 $29,761 - $76,446
-19,452 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.7 - $4.08 $33,068 - $79,364
19,452 New
19,452 $34,000

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $25.7M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.